Although several prognostic signatures have been developed in lung cancer, their
application in clinical practice has been limited because they have not been validated in …

Abstract In Non—Small-cell lung cancer (NSCLC), molecular profiling of tumors has led to
the identification of gene expression patterns that are associated with specific phenotypes …

Background Stage I lung adenocarcinoma is usually not treated with adjuvant
chemotherapy; however, around half of these patients do not survive 5 years. Therefore, a …

Tumor recurrence is the major cause of death in lung cancer treatment. To date, there is no
clinically applied gene expression-based model to predict the risk for tumor recurrence in …

A substantial number of studies have reported the development of gene expression–based
prognostic signatures for lung cancer. The ultimate aim of such studies should be the …

Disease recurrence in surgically treated lung adenocarcinoma (AC) remains high. New
approaches for risk stratification beyond tumor stage are needed. Gene expression‐based …

Purpose Recently, several expression-profiling experiments have shown that
adenocarcinoma can be classified into subgroups that also reflect patient survival. In this …

Purpose: Improving outcomes for early-stage lung cancer is a major research focus at
present because a significant proportion of stage I patients develop recurrent disease within …

Purpose: Identification of effective markers for outcome is expected to improve the clinical
management of non–small cell lung cancer (NSCLC). Here, we assessed in NSCLC the …

Background Several different gene expression signatures have been proposed to predict
response to therapy and clinical outcome in lung adenocarcinoma. Herein, we investigate if …